Among patients who experienced an early cardiovascular event, those treated with semaglutide had approximately 40% fewer ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Discover how semaglutide reduces heart attack and stroke risk by 20% in overweight individuals, with benefits appearing ...

A study in weight loss drugs where one third of participants were given a placebo turned out to have some impressive results.

In SELECT, semaglutide showed a 20% reduction in major adverse cardiovascular events (MACE) – including cardiovascular death, non-fatal heart attack, or non-fatal stroke – with the benefits ...

The SELECT trial, first conducted in 2023, demonstrated that semaglutide could reduce the risk of major heart events—such as ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular ... major cardiovascular events, with significant benefits already evident by the first 6 months, and for some ...

Sanyal noted that semaglutide had previously been shown to be beneficial for obesity, diabetes and heart disease. Looking ahead, the research team plans to gather data from nearly 1,200 ...

Together, with the established benefits of semaglutide for diabetes, obesity and heart disease, this is a major step forward for patients with MASH, who often have obesity and diabetes and are at ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic ...